This portion of our Web site contains archived information. Archived Information contained or referenced herein should not be considered current and may no longer be accurate.
 |
Aug 14, 2008
Dendreon Initiates Second of Two New Phase 2 Trials |
10.4 KB |
| |
SEATTLE, WASHINGTON, August 14, 2008 — Dendreon Corporation (Nasdaq: DNDN) today announced that the Company has initiated its second of two new Phase 2 trials of PROVENGE® (sipuleucel-T), Dendreon's investigational active cellular immunotherapy for the treatment of advanced prostate cancer. The multicenter trial, called P...
|
|
Aug 12, 2008
Dendreon Reports Second Quarter 2008 Financial Results |
37.5 KB |
| |
SEATTLE, WASHINGTON August 12, 2008 — Dendreon Corporation (Nasdaq: DNDN) reported results for the quarter ended June 30, 2008.
Revenue for the second quarter of 2008 was $26,000 compared to $523,000 for the quarter ended June 30, 2007. Revenue for the six months ended June 30, 2008 was $57,000 compared to $603...
|
|
Aug 7, 2008
Dendreon to Hold Conference Call on Tuesday, August 12, 2008 at 4:30 PM ET |
8.0 KB |
| |
SEATTLE, August 7, 2008 — Dendreon Corporation (Nasdaq: DNDN) will hold its second quarter earnings call on Tuesday, August 12, 2008. Company management will host the conference call at 1:30 p.m. PT (4:30 p.m. ET) to review second quarter financial results. Access to the discussion may be obtained as follows:
Read more
|
|
Jul 23, 2008
Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October |
10.8 KB |
| |
*** Your Title Here ***
SEATTLE, WASHINGTON, July 23, 2008 — Dendreon Corporation (Nasd...
|
|
Jul 16, 2008
Dendreon Initiates Phase 2 Trial of PROVENGE in Patients with Localized Prostate Cancer Prior to Surgery |
11.8 KB |
| |
SEATTLE, WASHINGTON, July 16, 2008 – Dendreon Corporation (Nasdaq: DNDN) today announced that the Company has initiated a Phase 2 trial of PROVENGE® (sipuleucel-T), Dendreon's investigational active cellular immunotherapy for the treatment of prostate cancer, in men with localized prostate cancer who are scheduled to under...
|
|
Jun 4, 2008
Dendreon Announces Webcast Presentation at Needham 7th Annual Biotechnology and Medical Technology Conference |
7.2 KB |
| |
SEATTLE, June 4, 2008 – Dendreon Corporation (Nasdaq: DNDN) today announced that Greg Schiffman, chief financial officer of Dendreon, will present a company update at the Needham 7th Annual Biotechnoloy and Medical Technology Conference in New York City, on Wednesday, June 11, 2008 at 9:30 a.m. ET.
A live audio w...
|
|
May 21, 2008
Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia |
11.4 KB |
| |
-- Data Presented at American Urological Association Annual Meeting --
SEATTLE and ORLANDO, Fla., May 21, 2008 - Researchers from Dendreon Corporation (Nasdaq: DNDN) today presented preclinical data demonstrating the potential of D-3263, Dendreon's orally bioavailable small molecule, which targets Trp-p8 (a transmemb...
|
|
May 8, 2008
Dendreon Reports First Quarter 2008 Financial Results |
31.7 KB |
| |
SEATTLE, May 8, 2008 – Dendreon Corporation (Nasdaq: DNDN) today reported results for the first quarter ended March 31, 2008. Revenue for the first quarter of 2008 was $31,000 compared to $80,000 for the quarter ended March 31, 2007.
Dendreon's total operating expenses for the three months ended March 31, 2008 ...
|
|
Apr 30, 2008
Dendreon Announces Webcast Presentations at Upcoming Investor Conferences |
7.1 KB |
| |
SEATTLE, WA, April 30, 2008 - Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the following investor conferences in May.
Deutsche Bank 33rd Annual Health Care Conference
InterContinental Boston
Tuesday, May 6, 2008
8:50 a.m. ET
Bank of America Health Care Conference
F...
|
|
Apr 8, 2008
Dendreon Announces Closing of Registered Direct Offering |
8.4 KB |
| |
SEATTLE, WASHINGTON, April 8, 2008 - Dendreon Corporation (Nasdaq: DNDN) today announced that it has completed the previously announced registered direct offering of 8.0 million shares of its common stock and warrants to purchase up to 8.0 million shares of its common stock. Net proceeds received by Dendreon were approximately ...
|
|
Apr 3, 2008
Dendreon Announces $47 Million Registered Direct Offering |
9.2 KB |
| |
SEATTLE, WASHINGTON, April 3, 2008 - Dendreon Corporation (Nasdaq: DNDN) today announced that it has entered into a definitive agreement with an institutional investor to sell 8.0 million shares of its common stock and warrants to purchase up to 8.0 million shares of its common stock for gross proceeds of approximately $47 million, before...
|
|
Mar 13, 2008
Dendreon Reports Fourth Quarter and 2007 Year End Financial Results |
25.6 KB |
| |
Dendreon Reports Fourth Quarter and 2007 Year End Financial Results Dendreon Reports Fourth Quarter and 2007 Year End Financial Results - Dendreon to Hold Conference Call Today, March 13, 2008 at 11:00 AM ET -SEATTLE, WA, March 13, 2008Read more
|
|
Mar 12, 2008
FDA Agrees to Amend Dendreon's Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE |
12.0 KB |
| |
-- Amended Agreement Accelerates Expected Timing of Final Analysis by One Year While Maintaining Comparable Powering of Interim and Final Results --
- Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET -
SEATTLE, WA, March 12, 2008 - Dendreon Corporation (Nasdaq: DNDN) ...
|
|
Mar 6, 2008
Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET |
8.5 KB |
| |
SEATTLE, March 6, 2008 - Dendreon Corporation (Nasdaq: DNDN) will release its fourth quarter financial results on Thursday, March 13, 2008. Company management will host a conference call at 8:00 a.m. PT; 11:00 a.m. ET to review fiscal year 2007 financial results and provide 2008 financial guidance. Access to the discussion may be obtain...
|
|
Feb 27, 2008
Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation |
9.7 KB |
| |
SEATTLE, Feb. 27, 2008 - Dendreon Corporation (Nasdaq: DNDN) announced the publication of a manuscript titled, "CD54 is a surrogate marker of antigen presenting cell activation" in Cancer Immunology, Immunotherapy.
The manuscript describes and supports the use of CD54 as a surrogate marker of antigen presenting...
|
|
Feb 14, 2008
Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE® to Overall Survival |
11.5 KB |
| |
SEATTLE and SAN FRANCISCO, February 14, 2008 - Researchers from Dendreon Corporation (Nasdaq: DNDN) today presented data demonstrating the correlation of a measure of the cumulative potency of PROVENGE (sipuleucel-T), an investigational active cellular immunotherapy for hormone-refractory prostate cancer, with overall survival. ...
|
|
Feb 7, 2008
Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference |
7.8 KB |
| |
SEATTLE, February 7, 2008 - Dendreon Corporation (Nasdaq: DNDN) today announced that Mitchell H. Gold, M.D., chairman and chief executive officer of Dendreon, will present a company update at the 10th Annual BIO CEO & Investor Conference in New York City, on Wednesday, February 13, 2008 at 1:15 p.m. ET.
A live audio webcast of...
|
|
Jan 15, 2008
Dendreon Receives European Patent Covering PROVENGE® and Company's ACI Platform Technology |
11.2 KB |
| |
SEATTLE, WA, January 15, 2008 - Dendreon Corporation (Nasdaq: DNDN) today announced that the company has been granted a broad European patent covering the company's lead product candidate PROVENGE® (sipuleucel-T), the Company's investigational active cellular immunotherapy for the treatment of advanced prostate cancer. European...
|
| Showing 1-18 of 18 |
Page: 1 |
|
|
